Alimera Scienc…
ProfileJobs

Alimera Sciences

Suggest Edit
    • Healthbiotechdrug developmentpharma

    Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.

    Revenue(FY, 2016)
    $34.3 M
    Market capitalization(2018-07-11)
    $69.4 M
    Type
    Public
    HQ
    Alpharetta, US
    Founded
    2003
    Size (employees)
    125 (est)
    Website
    alimerasciences.com
    Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US
    Report incorrect company information

    Key People/Management at Alimera Sciences

    Ken Greene

    Ken Greene

    CSO
    Susan Caballa

    Susan Caballa

    Sr. Vice President, Regulatory & Medical Affairs
    Philip Ashman

    Philip Ashman

    SVP & European Managing Director
    Rick Eiswirth

    Rick Eiswirth

    President & CFO
    Dave Holland

    Dave Holland

    SVP of Sales & Marketing
    Show more

    Alimera Sciences Office Locations

    Alimera Sciences has offices in Hampshire, Alpharetta, Berlin and Lisbon
    Alpharetta, US (HQ)
    6120 Windward Pkwy
    Berlin, DE
    21 Cicerostraße
    Hampshire, GB
    Wellesley Rd
    Show all (4)
    Report incorrect company information

    Alimera Sciences Financials and Metrics

    Alimera Sciences Revenue

    Alimera Sciences's revenue was reported to be $34.33 m in FY, 2016 which is a 53% increase from the previous period.
    USD

    Revenue (Q1, 2018)

    		9.8 m

    Net income (Q1, 2018)

    		(7.7 m)

    Market capitalization (11-Jul-2018)

    		69.4 m

    Closing share price (11-Jul-2018)

    		1

    Cash (30-Jun-2017)

    		26.9 m
    Alimera Sciences's current market capitalization is $69.4 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Revenue

    		1.9 m8.4 m22.4 m34.3 m

    Revenue growth, %

    		350%166%53%

    Cost of goods sold

    		1.9 m

    Gross profit

    		9 k
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		758 k2.1 m2.2 m2.4 m3.9 m5.8 m6.9 m5.8 m9.6 m8.3 m6.6 m10.4 m9.8 m

    Cost of goods sold

    		57 k564 k376 k

    Gross profit

    		701 k1.5 m1.8 m

    Gross profit Margin, %

    		92%73%83%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		12.6 m76.7 m31.1 m31 m

    Accounts Receivable

    		500 k850 k9.8 m13.8 m

    Inventories

    		3.5 m3.2 m2.7 m446 k

    Current Assets

    		18.6 m83.3 m45.2 m47.4 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    Cash

    		23.1 m41.3 m42 m61.4 m61.3 m48.1 m39.3 m23.9 m16.6 m33.9 m26.7 m26.9 m

    Accounts Receivable

    		464 k1.3 m1 m1.1 m3.4 m7.7 m9.4 m9.1 m13.3 m13.4 m10.8 m13.6 m

    Inventories

    		3 m1.2 m1.4 m1.7 m2.1 m1.6 m1.7 m1.4 m1.2 m913 k802 k1.1 m

    Current Assets

    		30.1 m46.5 m47.5 m67.3 m70.3 m61.1 m53.4 m37.2 m34.7 m51.6 m40.5 m44.3 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		(46.2 m)(35.9 m)(30.6 m)(33.2 m)

    Depreciation and Amortization

    		138 k659 k2.6 m2.8 m

    Inventories

    		(1.4 m)206 k405 k1 m

    Accounts Payable

    		(259 k)3 m(487 k)1.1 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Net Income

    		(31.5 m)(20.8 m)(19.6 m)(26.7 m)(9.8 m)(18.4 m)(19.9 m)(11.1 m)(18 m)(27.2 m)(6.7 m)(9.5 m)(7.7 m)

    Depreciation and Amortization

    		101 k36 k69 k151 k558 k1.2 m1.9 m689 k1.4 m2.1 m666 k1.3 m649 k

    Inventories

    		(2.2 m)548 k400 k(9 k)(455 k)(16 k)(88 k)164 k301 k612 k(361 k)(719 k)299 k

    Accounts Payable

    		717 k111 k122 k1.3 m272 k(1.2 m)(1.4 m)(1.5 m)264 k(2.1 m)(1.1 m)572 k(992 k)
    show all
    Show all financial metrics
    Report incorrect company information

    Competitors

    MyoKardia
    Health - Public
    Athersys
    Health - Public
    Neurocrine Biosciences
    Health - Public
    Ironwood Pharmaceuticals
    Health - Public
    Compare competitors

    Alimera Sciences Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Alimera Sciences News and Updates

    June 21, 2018

    Alimera Sciences Appoints Mary T. Szela to its Board of Directors

    ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...
    June 21, 2018

    Alimera Sciences Appoints Mary T. Szela to its Board of Directors

    ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...
    May 06, 2018

    Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2018 Results - Earnings Call Transcript

    Report incorrect company information

    Alimera Sciences Company Life and Culture

    Report incorrect company information
    Download PDF